Longeveron Inc. (LGVN) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

6/25

Growth 1 Margin 1 Expansion 3 Platform 1 Financial 0

latest quarter score

Earnings Reports

6
Longeveron (LGVN) Q2 2026: Approaching Pivotal HLHS Data and XPRIZE Recognition Accelerate Strategic Momentum
August 17, 2026
8
Longevron (LGVN) Q1 2026: $15.8M Cash Extends Runway as HLHS Readout Nears
May 14, 2026
5
Longevron (LGVN) Q4 2025: $15M Capital Infusion Extends Runway to Pivotal HLHS Data
March 18, 2026
6
Longevron (LGVN) Q3 2025: R&D Spend Rises 52% as HLHS Pivotal Data Nears
November 05, 2025
6
LGVN Q2 2025: R&D Spending Jumps 39% as HLHS and Pipeline Acceleration Drive Near-Term Milestones
August 14, 2025
6
Longeveron (LGVN) Q1 2025: Near Completion of HLHS Trial Sets Stage for 2026 BLA Submission
May 08, 2025
Longeveron (LGVN) 2024: 237% Revenue Surge Driven by Clinical and Manufacturing Progress
February 28, 2025

Browse all companies